article thumbnail

Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease

The New England Journal of Medicine

In this multicenter, randomized trial, edoxaban monotherapy led to a lower risk of net clinical adverse events at 12 months than dual antithrombotic therapy in patients with atrial fibrillation and stable coronary artery disease.

article thumbnail

Prognostic implications of stress test-induced arrhythmias: a systematic review and meta-analysis

Open Heart

The presence of atrial fibrillation (AF) during stress testing was not associated with mortality at all time points: OR 1.53 (95% CI 0.05, 50.19), p=0.81. Atrial arrhythmia during stress testing, on the other hand, shows no association with mortality.

article thumbnail

Pathophysiology, Diagnosis, and Management of Coronary Artery Disease in the Setting of Atrial Fibrillation

Journal of the American Heart Association

Atrial fibrillation (AF) and coronary artery disease are frequently associated and, when so, lead to a grim prognosis. The clinical impact of correct assessment of coronary artery stenosis in AF is especially high, due to the antithrombotic therapy imposed by both AF and coronary stenting.

article thumbnail

Atrial Fibrillation: Understanding the Irregular Heartbeat

AMS Cardiology

Atrial fibrillation (AFib) is a common heart rhythm disorder characterized by an irregular and often rapid heartbeat. What is Atrial Fibrillation? Coronary Artery Disease : Blocked arteries can affect heart function and rhythm. Symptoms of Atrial Fibrillation Symptoms vary among individuals.

article thumbnail

Anthos Presents New Analysis from P2 AZALEA-TIMI 71 Study

DAIC

"Given the elevated bleeding risks associated with traditional anticoagulants, particularly when combined with antiplatelet agents, abelacimab may offer a safer alternative for patients with atrial fibrillation,” said Christian T. For more information, please visit anthostherapeutics.com.

article thumbnail

Atrial Fibrillation and Stable Coronary Artery Disease

The New England Journal of Medicine

Patients with atrial fibrillation are at high risk for stroke, and international guidelines recommend oral anticoagulant therapy. In patients with stable vascular disease without atrial fibrillation, antiplatelet therapy is recommended. When patients with both conditions present with.

article thumbnail

Edoxaban Versus Edoxaban With Antiplatelet Agent in Patients With Atrial Fibrillation and Chronic Stable Coronary Artery Disease

American College of Cardiology

The goal of the EPIC-CAD trial was to evaluate edoxaban monotherapy compared with edoxaban/antiplatelet therapy among patients with atrial fibrillation (AF) and chronic coronary disease.